Comparative Pharmacology
Head-to-head clinical analysis: ACETAMINOPHEN AND IBUPROFEN versus DIFLUNISAL.
Head-to-head clinical analysis: ACETAMINOPHEN AND IBUPROFEN versus DIFLUNISAL.
ACETAMINOPHEN AND IBUPROFEN vs DIFLUNISAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Acetaminophen is a centrally acting analgesic and antipyretic whose exact mechanism is not fully understood, but is thought to involve inhibition of cyclooxygenase (COX) in the brain and modulation of cannabinoid receptors. Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that non-selectively inhibits COX-1 and COX-2, reducing prostaglandin synthesis.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, reducing prostaglandin synthesis, thereby exerting analgesic, anti-inflammatory, and antipyretic effects.
Oral: Acetaminophen 325 mg and ibuprofen 200 mg, 1-2 tablets every 6 hours as needed, not exceeding 6 tablets/24 hours.
500 mg to 1000 mg orally initially, then 250 mg to 500 mg every 8 to 12 hours. Maximum daily dose: 1500 mg.
None Documented
None Documented
Clinical Note
moderateDiflunisal + Gatifloxacin
"Diflunisal may increase the neuroexcitatory activities of Gatifloxacin."
Clinical Note
moderateDiflunisal + Rosoxacin
"Diflunisal may increase the neuroexcitatory activities of Rosoxacin."
Clinical Note
moderateDiflunisal + Levofloxacin
"Diflunisal may increase the neuroexcitatory activities of Levofloxacin."
Clinical Note
moderateDiflunisal + Trovafloxacin
"Diflunisal may increase the neuroexcitatory activities of Trovafloxacin."
Acetaminophen: 2-3 hours (normal hepatic function). Ibuprofen: 2-4 hours (immediate-release); prolonged in overdose or hepatic impairment.
8-12 hours (prolonged in renal impairment; clinical context: permits twice-daily dosing)
Acetaminophen: renal excretion of metabolites (glucuronide 55%, sulfate 30%, cysteine/mercapturate <10%); <5% unchanged. Ibuprofen: renal excretion of metabolites (conjugates) 90%; <10% unchanged; minor biliary/fecal.
Renal (90% as glucuronide conjugates, <5% unchanged); biliary/fecal (<10%)
Category D/X
Category C
NSAID
NSAID